Sangamo advances Fabry gene therapy with pivotal STAAR data

An update from Sangamo Biosciences ( (SGMO) ) is now available.

On February 3, 2026, Sangamo Therapeutics reported detailed clinical data from its registrational Phase 1/2 STAAR study of its Fabry disease gene therapy candidate isaralgagene civaparvovec (ST-920), covering 33 treated patients as of an April 10, 2025 cutoff and timed to presentations at the 22nd Annual WORLDSymposium in San Diego. The completed Phase 1/2 trial, in which 32 patients had at least 52 weeks of follow-up and all eligible participants rolled into a long-term extension, showed that ST-920 was generally well tolerated without preconditioning, with mostly mild to moderate adverse events, only one treatment-related serious adverse event, no thrombotic microangiopathy, no treatment-related discontinuations and no deaths. Patients demonstrated sustained normal to supraphysiological α-Gal A activity, reductions or stabilization in lyso-Gb3, and, notably, all 18 patients who entered the study on enzyme replacement therapy were able to discontinue it under supervision, while maintaining biochemical control in most cases; antibody titers against α-Gal A also decreased or became undetectable in the majority of those with baseline antibodies. Kidney function, assessed via mean annualized eGFR slope at 52 and 104 weeks, was positive and compared favorably with historical data from approved Fabry therapies, with supportive subgroup analyses, while cardiac structure and function remained stable over 52 weeks and patients showed statistically significant improvements in disease severity measures, quality of life and gastrointestinal symptoms. On the regulatory front, the U.S. FDA agreed in October 2025 that data from this Phase 1/2 STAAR study can serve as the primary basis for potential approval under the Accelerated Approval Program using 52-week eGFR slope as an intermediate endpoint, and Sangamo began a rolling Biologics License Application submission in December 2025, positioning ST-920 as a potential first gene therapy alternative to chronic enzyme replacement in Fabry disease and marking a key milestone in the company’s rare-disease gene therapy strategy.

The most recent analyst rating on (SGMO) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Sangamo Biosciences stock, see the SGMO Stock Forecast page.

Spark’s Take on SGMO Stock

According to Spark, TipRanks’ AI Analyst, SGMO is a Neutral.

The score is held down primarily by weak financial performance: sharply lower revenue, ongoing losses and cash burn, and a weakened equity/leverage profile. Technicals are mixed (short-term improvement but longer-term downtrend), valuation remains constrained by negative earnings, while the earnings call provides a notable offset due to encouraging clinical/FDA updates and a modestly improved cash runway despite continued funding risk.

To see Spark’s full report on SGMO stock, click here.

More about Sangamo Biosciences

Sangamo Therapeutics is a biotechnology company focused on developing genetic medicines, including gene therapies, for serious inherited diseases. Its wholly owned pipeline includes isaralgagene civaparvovec (ST-920), an investigational adeno-associated virus (AAV)-based gene therapy targeting Fabry disease, a rare lysosomal storage disorder primarily managed today with chronic enzyme replacement therapy.

Average Trading Volume: 6,638,442

Technical Sentiment Signal: Sell

Current Market Cap: $180.2M

For detailed information about SGMO stock, go to TipRanks’ Stock Analysis page.